Caradise Ghana Facilitates Transportation for MMV and Novartis Following Historic Coartem® Baby Launch in Ghana

Caradise Ghana has successfully facilitated the transportation and bus rental needs of executives and researchers from Medicines for Malaria Venture (MMV) and Novartis following the historic launch of Coartem Baby in Ghana.

Ghana became the first malaria-endemic country to launch Coartem® (artemether-lumefantrine) Baby, the first malaria treatment specifically designed and approved for young infants. 

Developed by Novartis in collaboration with MMV, Coartem Baby closes a critical treatment gap for the youngest and most vulnerable patients: newborns. Until now, infants under 4.5 kg had no approved malaria treatment and were either administered formulations intended for older children, increasing the risk of overdose and toxicity or underdose, increasing the risk of treatment failure.

The fleet of buses and vans from Caradise Ghana transported high-level executives and researchers from MMV and Novartis seamlessly over the course of four days, following the launch of the breakthrough drug.

Alkistis Evangelidou, Events Manager for MMV, was especially grateful for the excellent services from Caradise Ghana, stating “Everything was handled with such professionalism and attention to detail, from the airport pickups to the hotel transfers and the transport arrangements in Accra for the visit to the key location.”